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Abstract
Background: Alternative splicing is an important and widespread mechanism for generating protein diversity and
regulating protein expression. High-throughput identification and analysis of alternative splicing in the protein level
has more advantages than in the mRNA level. The combination of alternative splicing database and tandem mass
spectrometry provides a powerful technique for identification, analysis and characterization of potential novel
alternative splicing protein isoforms from proteomics.
Therefore, based on the peptidomic database of human protein isoforms for proteomics experiments, our objective
is to design a new alternative splicing database to 1) provide more coverage of genes, transcripts and alternative
splicing, 2) exclusively focus on the alternative splicing, and 3) perform context-specific alternative splicing analysis.
Results: We used a three-step pipeline to create a synthetic alternative splicing database (SASD) to identify novel
alternative splicing isoforms and interpret them at the context of pathway, disease, drug and organ specificity or
custom gene set with maximum coverage and exclusive focus on alternative splicing. First, we extracted
information on gene structures of all genes in the Ensembl Genes 71 database and incorporated the Integrated
Pathway Analysis Database. Then, we compiled artificial splicing transcripts. Lastly, we translated the artificial
transcripts into alternative splicing peptides.
The SASD is a comprehensive database containing 56,630 genes (Ensembl gene IDs), 95,260 transcripts (Ensembl
transcript IDs), and 11,919,779 Alternative Splicing peptides, and also covering about 1,956 pathways, 6,704
diseases, 5,615 drugs, and 52 organs. The database has a web-based user interface that allows users to search,
display and download a single gene/transcript/protein, custom gene set, pathway, disease, drug, organ related
alternative splicing. Moreover, the quality of the database was validated with comparison to other known
databases and two case studies: 1) in liver cancer and 2) in breast cancer.
Conclusions: The SASD provides the scientific community with an efficient means to identify, analyze, and
characterize novel Exon Skipping and Intron Retention protein isoforms from mass spectrometry and interpret
them at the context of pathway, disease, drug and organ specificity or custom gene set with maximum coverage
and exclusive focus on alternative splicing.
Background
Alternative splicing is a widespread mechanism for gener-
ating protein diversity and regulating protein expression
with multiple splice isoforms. It was thought that at least
40-60% of human genes underwent alternative splicing to
encode two or more splice isoforms [1]. Recent advances
in high-throughput technologies have facilitated studies of
genome-wide alternative splicing. These studies estimate
that the prevalent post-transcriptional gene regulation
mechanism affects greater than 95% of roughly 61,000
human genes and multiple regulatory processes, including
chromatin modification and signal transduction [2].
Furthermore, there are evidences for alternatively splicing
events that are often differentially regulated across tissue
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types and developmental stages, as well as among indivi-
duals and populations, suggesting that individual isoforms
may serve specific spatial or temporal roles [3-5].
Alternative splicing is known to be involved in the reg-
ulation of normal physiological functions as well as
pathologies. The alternative splicing isoform represents a
new class of diagnostic biomarkers. Not only alternative
splicing is thought to increase protein diversity of gen-
omes, but also it has been found that splicing variants
have been associated with numerous disease develop-
ment and cancer cell growth. For example, David et al.
found that aberrant expression of the splicing factors
PTB, hnRNPA1 and hnRNPA2, regulated by the c-Myc
oncogene, was responsible for the PKM1 to PKM2 switch
in cancer [6]. This work helped us understand the alter-
native splicing’s role in the cancer cell growth. Eswaran
et al. systematically revealed splicing signatures of the
three most common types of breast tumors using RNA
sequencing: TNBC, non-TNBC and HER2-positive breast
cancer and discovered subtype specific differentially
spliced genes and splice isoforms not previously recog-
nized in human transcriptome. They validated the pre-
sence of novel hybrid isoforms of critical molecules like
CDK4, LARP1, ADD3, and PHLPP2 and found that exon
skip and intron retention are predominant splice events
in breast cancer [7]. Yae et al. found that epithelial spli-
cing regulatory protein 1 regulates the expression of a
CD44 variant isoform (CD44v), and knockdown of
epithelial splicing regulatory protein 1 in CD44v+ cells
results in an isoform switch from CD44v to CD44 stan-
dard (CD44s), leading to reduced cell surface expression
of xCT and suppression of lung colonization. They sug-
gested that the epithelial splicing regulatory protein
1-CD44v-xCT axis was thus a potential therapeutic target
for the prevention of metastasis [8].
Recent methodological advances, including EST
sequencing, exon array, exon-exon junction array, and
next-generation sequencing of all mRNA transcripts,
have made it possible to perform high-throughput alter-
native splicing analysis [7]. However, high-throughput
identification and analysis of alternative splicing in the
protein level has several advantages. For example, mRNA
abundance in a cell often correlates poorly with the
amount of protein synthesized, and proteins rather than
mRNA transcripts are the actual major effector mole-
cules in the cell.
The combination of alternative splicing database and tan-
dem mass spectrometry provides a powerful technique for
identification, analysis and characterization of potential
novel alternative splicing protein isoforms from proteomics.
In recent years, liquid chromatography tandem mass spec-
trometry (LC-MS/MS) has emerged as an innovative analy-
tical technology applicable to a wide number of analyses
including high-throughput identification of proteins [9].
LC-MS/MS proteomics has been used to identify candidate
molecular biomarkers in diverse range of samples, includ-
ing cells, tissues, serum/plasma, and other types of body
fluids. Due to the inherent high variability of both clinical
samples and MS/MS instruments, it is still challenging to
quantify minute changes of proteins that exist in trace
amount in response to changes in disease states of biologi-
cal samples. Identifying alternative splicing isoform relevant
to disease can improve both sensitivity and specificity of
candidate disease biomarkers because many proteins could
generate abundant alternative splicing isoforms in a disease,
some of them may be exclusively regulated in a given dis-
ease condition, and therefore their identification process is
often sufficient to distinguish between disease samples and
controls [10].
However, without a proper alternative splicing data-
base, tandem mass spectrometry could not discriminate
against novel alternative splicing peptides [10,11].
Searching traditional protein sequence databases which
are commonly used by peptide/protein search engine
such as 1) IPI [12], 2) NCBI nr (ftp://ftp.ncbi.nih.gov/
blast/db/FASTA/nr.gz), and 3) UniProt [13] biases the
results towards well-understood protein isoforms
because they contains a rather small set of splicing pep-
tides and not enough for the identification of alternative
splicing isoform from mass spectrometry data.
There are also currently several alternative splicing data-
bases, for example, ASTD [14], EID [15,16], Fast DB [17],
and ECgene [18]. They are not suitable for being directly
applied to novel alternative splicing isoform identification
without proper modifications made in format and content,
because either their coverages are all relatively small in
possible combination of alternative splicing junctions such
as intron-exon, exon-intron, or non-neighboring exon, or
single intron, or their storage formats make the databases
difficult to use for mass spectrometry analysis and alterna-
tive splicing analysis.
Therefore, there is an urgent need to build an alternative
splicing database which can be used by tandem mass spec-
trometry to identify the novel alternative splicing isoform.
In 2010, we developed the PEPtidomics Protein Isoform
Database (PEPPI [10], http://bio.informatics.iupui.edu/
peppi), a database of computationally-synthesized human
peptides that can identify protein isoforms derived from
either alternatively spliced mRNA transcripts or SNP var-
iations. We collected genome, pre-mRNA alternative spli-
cing and SNP information from Ensembl and synthesized
in silico isoform transcripts that cover all exons and theo-
retically possible junctions of exons and introns, as well as
all their variations derived from known SNPs.
Based on the PEPPI [10], our objective is to design a
new alternative splicing database to 1) provide more
coverage of genes, transcripts and alternative splicing, 2)
exclusively focus on the alternative splicing (we will
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build another database excusive to SNP isoform), and 3)
perform context-specific alternative splicing analysis.
More coverage means more sensitivity in identifying
novel alternative splicing isoforms. Exclusive focus on
alternative splicing can increase the specificity of the
identification of alternative splicing. Context specificity
analysis can improve our understanding of alternative
splicing’s roles in the context.
Splicing events often lead to enormous differences
among isoforms in their sequences and structures and in
the interactions, pathway networks, diseases, drugs, and
organs formed. An enormous body of evidence has
demonstrated the roles of alternative splicing in determin-
ing tissue-specific and species-specific differentiation pat-
terns [2]. However, of interest is not only how it can
respond to various signaling pathways, disease treatments
and drug actions that target the splicing machinery but
also what are the differences in pathways, diseases and
drugs between different isoforms are generally overlooked.
Therefore, it is crucial to the advance of basic and medical
research that alternative splicing isoforms are interpreted
and analyzed on a basis of context: pathway, disease, drug
and organ because alternative splicing isoforms occur in a
particular pathway, disease, drug action, or organ and we
need to know about not only the isoforms themselves, but
also their context regarding where they develop and stage.
We created the Synthetic Alternative Splicing Data-
base (SASD) for users to detect specific alternative spli-
cing isoforms and interpret their context at the pathway,
disease, drug and organ level with maximum coverage
and exclusive focus on alternative splicing. First, we
extracted information on gene structures of all genes in
the Ensembl Genes 71 database [19] and incorporated
the IPAD database [20]. Then, we compiled artificial
splicing transcripts. Lastly, we translated the artificial
transcripts into alternative splicing peptides.
In addition, we built a web interface for users to
browse 1) by genes/proteins, 2) by context (custom
gene/protein set, signaling and metabolic pathway, dis-
ease, drug, and organ specificity).
In the end, we presented two case studies: 1) in liver
cancer and 2) in breast cancer to demonstrate that the
SASD can enable users to 1) identify novel alternative
splicing isoform, and 2) analyze, characterize, and
understand the impact of alternative splicing on genes
involved in drug, disease, pathway, function, and organ-
specificity.
The SASD, located at http://bioinfo.hsc.unt.edu/sasd is a
comprehensive database containing 56,630 genes
(Ensembl gene IDs), 95,260 transcripts (Ensembl transcript
IDs), and 11,919,779 Alternative Splicing peptides
(1,200,494 EXON_NM; 1,005,388 E_E_NM; 1,005,368
E_I_AS; 1,005,344 I_E_AS; 6,709,352 E_E_AS; and 993,833
INTRON_AS), and also covering about 1,956 pathways,
6,704 diseases, 5,615 drugs, and 52 organs incorporated
from the IPAD [20].
It is the first comprehensive database that can be used
for novel alternative splicing identification on the con-
text of pathway, disease, drug and organ specificity or
custom gene set. The maximum coverage and exclusive
focus on alternative splicing provide enough sensitivity
and specificity in identifying novel alternative splicing
isoforms. The context specificity analysis enables us to
improve our understanding of alternative splicing’s roles
in the context (custom gene set, pathway, disease, drug
and organ specificity).
The SASD provides the scientific community with an
efficient means to identify, analyze, and characterize
novel Exon Skipping and Intron Retention protein iso-
forms from mass spectrometry data. We believe that it
will be useful in annotating genome structures using
rapidly accumulating proteomics data and will assist
scientific research on signal transduction pathways regu-




The synthetic set of alternative splicing events (AS
events) is derived from Ensembl gene annotation [19].
The Ensembl gene set includes both automatic and man-
ual annotation, with all transcripts based on experimental
evidence. Alternatively splice from transcripts of any
given Ensembl gene are computationally synthesized and
automatically annotated to provide a comprehensive list
of six types of elementary alternative splicing events.
These data can be searched on the website by gene, pro-
tein, transcript, peptide sequence, disease, organ, drug,
and pathway. The AS events are available for the Homo
sapiens. In order to reflect specific isoform in the context
of pathway, disease, drug, and organ, the Integrated Path-
way Analysis Database (IPAD) [20] is also incorporated.
The IPAD [20] is the first comprehensive database for
enrichment and inter-association analysis between path-
way, disease, drug and organ. It was developed by inte-
grating pathway, disease, drug, and organ specificity
databases including BioCarta[21], KEGG[22], NCI-Nat-
ure curated[23], Reactome[24], CTD[25], PharmGKB
[26], DrugBank[27], and Homer[28].
As of the current release (May 2013), SASD contains
56,630 genes (Ensembl gene IDs), 95,260 transcripts
(Ensembl transcript IDs), and 11,919,779 Alternative
Splicing peptides (1,200,494 EXON_NM; 1,005,388
E_E_NM; 1,005,368 E_I_AS; 1,005,344 I_E_AS;
6,709,352 E_E_AS; and 993,833 INTRON_AS) (Table 1),
and also covers about 1,956 pathways, 6,704 diseases,
5,615 drugs, and 52 organs incorporated from the IPAD
[20]. A comparison of alternative splicing in SASD
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against several common alternative splicing data sources
is shown in Table 2.
General online features
In Figure 1, we show the user interfaces of the web-based
online version of SASD. It supports a powerful search
options that allow users to specify a list of genes/proteins
as the query input. Users can use different identifiers to
query the database. The recommended terms are
Ensembl gene ID, Ensemble transcript ID, Unigene ID’s,
Entrenz gene ID’s, Gene name, Uniprot ID’s, and IPI
ID’s. Users can enter a single gene or protein or multiple
values delimited by comma, semi-colon, line, or space.
Some interesting features of SASD include the ability
to be queried by multiple genes/proteins, pathway, dis-
ease, drug, and organ, to be searched by keyword in the
Search Box over the table, and to support three different
views for alternative splicing events: gene view, tran-
script view and region view.
In response to the query input, SASD can retrieve a
list of related alternative splicing events (gene, tran-
script, mode, type, and sequence) in a highly flexible
table, with which users can further explore details about
gene view, transcript view and region view of the alter-
native splicing events. For example, users can browse
the gene view and transcript view by clicking on the
link in the column of gene and transcript, respectively,
and look through the genomic sequences of junction,
splicing type, and peptide sequence in the region view
by clicking on the R icon in the ID column. There are
totally six types of alternative splicing events:
EXON_NM, E_I_AS, E_E_NM, E_E_AS, INTRON_AS,
and I_E_AS (Figure 2). AS stands for alternative splicing,
and NM for normal splicing. Different colors are used to
separate the junctions. Exon skipping event includes
E_E_AS. Intron retention event includes E_I_AS,
I_E_AS, and INTRON_AS. The Normal splicing is a
normal RNA splicing, in which all introns are removed
and the rest exons are joined into a contiguous
sequence (http://www.dnalc.org/resources/animations/
rna-splicing.html). In contrast, in the process of alterna-
tive splicing, particular exons or introns of a gene may
be included within, or excluded from the final, pro-
cessed messenger RNA produced from that gene (http://
www.eurasnet.info/education/alternate-splicing/what-is-
alternate-splicing). Noted: in E_I_AS, E_E_AS, INTRO-
N_AS and I_E_AS, we use alternative splicing’s original
and narrow definition. But when we say SASD contains
six types of alternative splicing, we use its generalized
definition which includes not only narrowly defined
alternative splicing but also normal splicing.
User queried alternative splicing data stored in SASD
can also be downloaded as tab-delimited text and fasta
format files when clicking on links below each alterna-
tive splicing table. The fasta format files can be run by
any mass spectrometry search engine for alternative spli-
cing identification.
Table 1 current statistics of database








Genes 56,630 (Ensembl gene ids)
Transcripts 95,260 (Ensembl transcript ids)
Table 2 a comparison of alternative splicing in SASD against several common alternative splicing data sources
ASTD[14] EID[15,16] ECgene[18] PEPPI[10] SASD
AS coverage 9405 62,474 185,174 5,324,542 11,919,779
gene coverage 16,710 11,242 37,204 23,516 56,630
Last Updated 2008 2000 July 2007 Feb 2010 May 2013
Curation Type Manual Synthetic Synthetic Synthetic Synthetic
Query by single gene No No No Yes Yes
Query by Pathway No No No No Yes
Query by Disease No No No No Yes
Query by Drug No No No No Yes
Query by Organ No No No No Yes
Query by custom gene set No No No No Yes
Query by gene sequence No No No Yes Yes
Gene view No No No Yes Yes
Transcript view No No No No Yes
Region view No No No Yes Yes
Peptide sequence No No No Yes Yes
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Figure 1 Web interface structure. a) Query by genes or proteins. For example, Ensembl Gene ID, Ensembl Transcript ID, UniGene IDs, Entrez gene
IDs, gene names, UniProt IDs, UniProt Accessions or IPI IDs are all supported. To enter multiple values, delimit them by comma, semi-colon, line or
space. b) search result. In the alternative splicing analysis table, it shows Query ID, SASD ID, Ensembl Gene ID, Ensembl Transcript ID, Mode, and Type.
For each alternative splicing event, users can further browse its region view, gene view and transcript view by clicking on the links at the right corners
of Column ID, Column Gene, and Column Transcript. c) gene view d) transcript view e) region view. f) molecule inter-association. It shows molecule,
Gene Symbol, Pathway ID (Disease ID, Drug ID, Organ ID), and Pathway Name(Disease Name, Drug Name, Organ Name).
Figure 2 Six types of as events. The thick boxes represent exons and the thin boxes stand for introns. The orange lines stand for combination
of exon-exon or exon-intron.
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Case studies
We presented two case studies: 1)in liver cancer and 2)
in breast cancer, to demonstrate that the SASD can
enable users: 1) to identify novel alternative splicing iso-
form, and 2) to analyze, characterize, and understand
the impact of alternative splicing on genes involved in
drug, disease, pathway, function, and organ-specificity.
Case study 1: identification of novel alternative splicing
isoforms
The Human Liver Proteome Project (HLPP) is a large-
scale international collaborative initiative focusing on
the proteomic analysis of the human liver. It aims to
generate a comprehensive protein atlas of the human
liver, uncover the proteomic basis of liver development,
physiology and pathology and develop liver-specific
diagnostics and therapeutics. We downloaded eight
human fetal liver cytoplasm proteome data sets between
weeks 16 and 24 of gestation available through the
human liver proteome project web site (http://hlpic.
hupo.org.cn). The human fetal liver between weeks 16
and 24 of gestation is a major site of fetal hematopoiesis
and is at the critical turning point between immigration
and emigration of the hematopoietic system. Protein
profiling of its unique characteristics can help research-
ers understand the immigration and emigration process
and improve conventional liver therapy [29].
OMSSA [30] is an efficient search engine for identify-
ing MS/MS peptide spectra by searching libraries of
known protein sequences. OMSSA scores significant hits
with a probability score developed using classical hypoth-
esis testing, the same statistical method used in BLAST.
OMSSA searches protein libraries formatted for BLAST.
In order to use OMSSA to identify alternative splicing
isoforms, we first used the program formatdb to create
our own alternative splicing sequence library from the
fasta format file. Then we set OMSSA search parameters
and run OMSSA to search the alternative splicing
sequence library against the DTA files we merged from
the eight raw liver proteome data. Totally, we identified
17 Novel alternative splicing isoforms which were undis-
covered previously by the PEPPI [10] when we chose
only peptides with at least two hits of samples as true
peptides, of which 5 are left intron retention events, 2
right intron retention events, 6 single intron retention
events, and 4 exon skipping events (Table 3). Bold text is
the left part of the junction and italic text is the right
part. Splicing site is marked by ^ or (). ‘()’ means the spli-
cing site is shared by the left region and right region. For
example, the first peptide LISQIVSSIT(A)SLR is a syn-
thetic product of the ENST00000473885 in gene
ENSG00000243910 when its third intron is retained and
combined together with its forth exon. The alanine is the
shared splicing site between the intron and the exon.
Although it can be mapped to ENSP00000449325,
ENSP00000396212, ENSP00000412646, and ENSP000
00443475, there is no hit when mapping it to ENSG000
00243910’s currently existed proteins. Thus it can be
viewed as a novel alternative splicing isoform of
ENSG00000243910. OMSSA search engine also provides
a very good spectrum display and peak labeling and
matching. For example, the matched MS/MS spectrum
of the first peptide is shown in Figure 3.
Pathway enrichment analysis of the alternative splicing
variants identified suggested that the involvement of
these proteins especially in apoptosis. For example, the
tight junction protein 2 (ENSG00000119139, TJP2) has
been proposed to be a tumor suppressor gene. TJP2
protein and/or mRNA expression is either lost or
decreased in pancreatic, prostate, breast and lung adeno-
carcinomas, in testicular in situ carcinoma and in lung
squamous carcinoma. Exon 21 in the alternative splicing
LL^AKTQNK (non-neighboring combination of exon 15
and exon 21) we identified has been involved in 3 of 5
isoforms previously identified.
Case study 2: identification of novel alternative splicing
biomarkers
One of advantage of using SASD for alterative splicing
analysis is that it supports query by pathway, disease,
drug, organ, or user input gene set, which can be used
for context specific alternative splicing analysis at the
level of pathway, disease, drug, organ or any user speci-
fied gene set. In this case, we demonstrate how to use the
new function of SASD to identify, analyze and character-
ize cancer-specific alternative splicing isoforms derived
directly from cancer-specific genes. The ‘specific’ here
means: 1) the genes from which the alternative splicing
peptides are synthesized are linked to breast cancer in
previous findings; and 2) the alternative splicing markers
identified are significantly differentially expressed
between breast cancer samples and normal samples.
Breast cancer is the fifth most common cause of cancer
death (after lung cancer, stomach cancer, liver cancer and
colon cancer). Among women worldwide, breast cancer is
the most common cause of cancer death. In 2012, an esti-
mated 226, 870 new cases of invasive breast cancer were
expected to be diagnosed in women in the U.S., along with
63,300 new cases of non-invasive breast cancer. Tradi-
tional methods such as mammogram or biopsy can often
detect a tumor only after a malignancy is advanced and
may have metastasized to other organs. There is an urgent
need for developing new methods for earlier detection of
breast cancer. Cancer-specific splice isoforms has been
observed in a few cases. Cancer-specific alterations in
splice site selection can affect genes controlling cellular
proliferation, cellular invasion, angiogenesis, apoptosis and
multidrug resistance. Therefore, it is essential to develop
cancer-specific alternative splicing isoform to enable bio-
marker discoveries for early detection of breast cancer.
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We first downloaded 15 breast cancer related genes
from the Cancer Gene Census[31]: AKT1, BAP1,
BRCA2, CCND1, CDH1, EP300, ERBB2, ETV6, GATA3,
MAP2K4, NTRK3, PBRM1, PIK3CA, RB1, and TP53.
Then we created the 15 genes’ alternative splicing
sequence library from the fasta format file which we
downloaded from the database SASD after a query by
the 15 genes in the SASD. Lastly, we used the 15 breast
cancer related genes’ alternative splicing sequence
library to run OMSSA search against 40 normal plasma
and 40 breast cancer plasma. The plasma protein pro-
files of 40 samples from women diagnosed with breast
cancer and 40 samples from healthy volunteer women
as control were collected by the Hoosier Oncology
Group (HOG) (Indianapolis, IN, USA). Most of patients
involved were diagnosed with a stage II or III or earlier
breast cancer.
The following options for OMSSA were used when
identifying MS/MS peptide spectra: -e Trypsin (selecting
trypsin to use for theoretical protein digestion), -y 1
(allowing maximum 1 missed cleavage), -hl 10 (Maximum
10 peptide hitlist length per spectrum), -he 0.1 (EValue
cutoff 0.1), -x human (Homo sapiens to search), -te 2.0
(Mass tolerance 2.0Da), -tem monoisotopic (Mass search
type monoisotopic), -zl 1 (Charge handle: low bound 1),
-zh 3 (Charge handle: upper bound 3), -zt 3 (Minimum
charge to start using multiple charged products 3), -to
0.8 (Mass tolerance 0.8 Da), -tom monoisotopic (mass
Table 3 17 novel peptide isoforms identified in human fetal liver project
hits sequence gene transcript mode type
6 LISQIVSSIT(A)SLR ENSG00000243910 ENST00000473885 i3E4 i_E_AS
3 ELAEDGYSGVE^VR ENSG00000149273 ENST00000525690 E1i1 E_i_AS
2 AIVAIENPADVSVISS(R) ENSG00000173163 ENST00000427417 i2E3 i_E_AS
2 CLFKLSILIYSLGISV(G)QK ENSG00000069329 ENST00000299138 i2E3 i_E_AS
2 DQEGQDVLLF(I)DNIFR ENSG00000110955 ENST00000547250 i2E3 i_E_AS
2 DQEGQDVLLFID^NIFR ENSG00000110955 ENST00000552919 E6i6 E_i_AS
2 GAVLGAERPR ENSG00000120251 ENST00000507898 i1 INTRON_AS
2 GTLYIIKLSADIR ENSG00000115593 ENST00000419482 i8 INTRON_AS
2 GVTIFVVL(D)ER ENSG00000170289 ENST00000320005 i11E12 i_E_AS
2 IGGIGTVPVGR ENSG00000172244 ENST00000306862 i6 INTRON_AS
2 INAVQISE^KIFR ENSG00000183091 ENST00000397345 E102E182 E_E_AS
2 LL^AKTQNK ENSG00000119139 ENST00000377245 E15E21 E_E_AS
2 LPLQDVYK ENSG00000172244 ENST00000306862 i6 INTRON_AS
2 SPGAWEGGREDR ENSG00000160111 ENST00000291440 i2 INTRON_AS
2 VSMILQSP^VLILR ENSG00000087274 ENST00000264758 E2E8 E_E_AS
2 VTQWAEE(R) ENSG00000137177 ENST00000259711 E17E23 E_E_AS
2 WPDSQLAWFLR ENSG00000119844 ENST00000238855 i8 INTRON_AS
Figure 3 Spectrum of LISQIVSSIT(A)SLR. The blue lines represent b-ions. And the red lines represent y-ions.
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search type monoisotopic), and -zoh 2 (Maximum 2
charge state allowed for product ions).
With the one-sided Wilcoxon signed-rank test [32], 8
alternative splicing markers (Table 4) were found differ-
entially present (pvalue < 0.05) at cancer state, out of
which there are five exon skipping, two single intron
retention, and one left intron retention. All the 8 alterna-
tive splicing markers are not identified by the traditional
alternative splicing database including the IPI database
[12], the NCBI-nr database, and the UniProt knowledge
base [33], and the PEPPI [10].
Pathway analysis identified the cancer pathways
including Pancreatic cancer, Pathways in cancer, Pros-
tate cancer, Bladder cancer, Endometrial cancer, Non-
small cell lung cancer, which are linked with the eight
alternative splicing isoforms. The cancer-specific differ-
entially expressed variants offer novel biomarker candi-
dates that may function in breast cancer progression
and metastasis. For example, the BRCA2 gene belongs
to a class of genes known as tumor suppressor genes
and is the most well-known gene linked to breast cancer
risk. Bonnet et al. detected 20 variants of BRCA1 or
BRCA2 that happened on exons 3, 16, 17, 18 or 25
from 17 index cases selected from families undergoing
oncogenic consultations [34]. We identified a novel
alternative splicing variant of BRCA2 QTPKHISESL-
GAEVDPDMSWSSSLATPPTLSSTVLI(G)LLHSSVK on
the exon7 and exon11 as a non-neighboring exon-exon
event.
This case study shows that compared to traditional
alternative splicing database, the SASD can be more
useful in identification of novel alternative splicing mar-
kers specific to some pathways, diseases, drugs or organ
specification.
Discussion
In this paper, we have demonstrated that SASD can be
used to identify novel alternative splicing isoforms on
the context of pathway, disease, drug and organ specifi-
city or custom gene set. Its maximum coverage and
exclusive focus on alternative splicing provide enough
sensitivity and specificity in identifying novel alternative
splicing isoforms. The context specificity analysis
enables us to improve our understanding of alternative
splicing’s roles in the context (custom gene set, pathway,
disease, drug and organ specificity). In Case Study 1, we
illustrated the SASD’s ability to identify novel alternative
splicing isoform. In Case Study 2, we demonstrated how
to use the new function of SASD to identify cancer-spe-
cific markers for distinguishing breast cancer from nor-
mal samples.
Alternative splicing is a widespread mechanism for
generating protein diversity and regulating protein
expression. Five basic types of alternative splicing events
are generally recognized: 1) exon skipping, 2) intron
retention, 3) mutually exclusive exons, 4) alternative
donor site, and 5) alternative acceptor site. In exon skip-
ping, an exon may be spliced out of the primary tran-
script or retained. This is the most common mode in
mammalian pre-mRNAs. Intron retention is an event
where a sequence is spliced out as an intron or remains
in the mature mRNA transcript. Mutually exclusive
exons event happens when one of two exons is retained
in mRNAs after splicing, but not both. Alternative donor
site is an event where an alternative 5’ splice junction
(donor site) is used, changing the 3’ boundary of the
upstream exon. And alternative acceptor site is an event
where an alternative 3’ splice junction (acceptor site) is
used, changing the 5’ boundary of the downstream exon.
The SASD does not contain the last three types of
events. But actually, they all can be derived indirectly
from the two basic types: exon skipping and intron reten-
tion which are included in the SASD in the form of
E_E_AS, and E_I_AS, INTRON_AS, and I_E_AS, respec-
tively. For example, if two modes such as E1E3 and E2E4
happen at the same time, it is actually a mutually exclu-
sive exons event. Alternative 5’ donor site can be
detected by the type E_I_AS such as E1i1 in the SASD
where donor site i1 is remained. Alternative 3’ acceptor
site can be detected by the type I_E_AS such as i4E5 in
the SASD where acceptor site i4 is remained.
In addition, the SASD contains EXON_NM, E_E_NM,
and INTRON_AS. The two normal splicing types:
EXON_NM and E_E_NM are included as a contrast to
Table 4 8 cancer-specific peptide markers identified in breast cancer
Peptide sequence gene transcript mode type pvalue h c
SWGGRPQRMGAVPGGVWSAVLMGGAR ERBB2 ENST00000269571 i18 INTRON_AS 9.48E-05 4 20
QTPKHISESLGAEVDPDMSWSSSLATPPTLSSTVLI(G)LLHSSVK BRCA2 ENST00000380152 E7_E11 E_E_AS 8.57E-04 1 12
SLWLQSQPHFCCFWLTVTFPPPLQ^THRELAQSSHAQR NTRK3 ENST00000317501 i2_E3 i_E_AS 1.22E-02 2 10
WGLLLALLPPGAASTQ(A)VWTWMTR ERBB2 ENST00000269571 E1_E16 E_E_AS 1.22E-02 2 10
LSWNHVARALTLTQSLVSSVTSGK NTRK3 ENST00000559764 i2 INTRON_AS 1.39E-02 4 13
CQ(G)EPYHDIRFNLMAVVPDR BAP1 ENST00000460680 E3_E9 E_E_AS 3.33E-02 9 18
QVLP^VGVLGPPGQQAPPPYPGPHPAGPPVIQQPTTPMFVAPPPK PBRM1 ENST00000296302 E9_E29 E_E_AS 3.89E-02 6 14
DHLACW^DYDLCITCYNTKNHDHK EP300 ENST00000263253 E22_E31 E_E_AS 4.50E-02 4 11
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the alternative splicing events. The INTRON_AS is
actually a complement of intron retention.
Some artificially synthetized peptides in the database
may not exist biologically. This will reduce computa-
tional efficiency but won’t affect the usage of the data-
base, as long as the following assumptions are met: if
some artificially synthetized peptides in the database
don’t actually exist biologically, they will less likely or
never match with proteome experimental spectra.
The SASD is similar to a modified peptide database
for Post Translational Modification (PTM) identification
from MS/MS. The first approach to PTM identification
proposed by Yates et al. [35], enumerating all possible
modifications for each peptide from the database still
works very well with small database. Enumerating all
possible mutations and modifications in the database
makes the database prohibitively large and is computa-
tionally expensive, so that using this kind of database to
search for modifications remains limited to smaller
databases.
One advantage of using SASD is context-based alter-
native splicing identification. Users can build a relatively
small database based on the context (pathway, disease,
disease, drug, and other user input gene set). This fea-
ture enables users not only to identify context-specific
alternative splicing, but also with significantly-improved
computational efficiency.
Fortunately, all search engines provide their own scores
as thresholds such as expectation value which is the
number of matches with equal or better scores that are
expected to occur by chance alone. In order to increase
the true discovery rate for these artificially synthetized
peptides that don’t exit biologically and that is less likely
or never to be identified by proteome experiments, when
using SASD, we recommend to use 1) the p-value (Mas-
cot) or evalue (OMSSA) as thresholds provided by var-
ious search engines and 2) cross-validation experiments.
That is, if a synthetic AS peptide is identified with signifi-
cant score and from more than n samples (for example,
n = 2), we say the synthetic AS peptide is identified and
the synthetic AS peptide exists biologically. More strin-
gent threshold or more experiment validations from
other labs or by other methods such as PCR are definitely




The overall pipeline of SASD comprises three steps: 1)
extracting information on gene structures of all genes in
the human genome and incorporating the IPAD data-
base [20], 2)compiling artificial splicing transcripts, and
3) translating the artificial transcripts into alternative
splicing peptides.
In the first step, we use the BioMart to extract infor-
mation on all human genes in the Ensembl [19] from
the Homo sapiens genes dataset (GRCh37.p10) in the
Ensembl Genes 71 database. We then extract informa-
tion on each human gene’s position, name, exon/intron
coordinates, exon phase, sequences, and annotation. The
information is organized in a relational database hosted
in a local SQL server 2012 database server.
In the second step, we generate artificial splicing tran-
script (AST), which is an exhaustive compilation of two
categories of peptides (the first is the peptides translated
from all single exons and introns, the second is the pep-
tides that covers all theoretically possible exon/intron
junction regions of all genes in the human genome). With
these two categories of peptides, both the whole sequence
of the genome and all possibilities of alternative splicing
are covered. In addition to single exon(EXON_NM) and
single intron (INTRON_AS), four types of exon/intron
sequence junctions are considered when generating ASTs:
intron-exon (I_E_AS, left intron retention junction), exon-
intron (E_I_AS, right intron retention junction), neighbor-
ing exon-exon (E_E_NM, normal splicing junction) and
non-neighboring exon-exon (E_E_AS, exon skipping junc-
tion). For each type, 120 nucleotides both upstream and
downstream of the joined sequence beside the junction
site are extracted, resulting in a computationally synthe-
sized virtual transcript of 240 nucleotides long. Determina-
tion of the number 120 is based on the length distribution
of fragment obtained from protein digestion in MS/MS
experiments. The boundaries where two components are
spliced are known as splicing sites. Totally, there are three
types of common splicing events: Normal Splicing, Exon
Skipping, and Intron Retention in the SASD. The Normal
Splicing includes single exon (EXON_NM) and neighbor-
ing exon-exon junction (E_E_NM), the Exon Skipping
includes non-neighboring exon-exon junction (E_E_AS),
and the Intron Retention includes single intron (INTRO-
N_AS), left intron retention junction (I_E_AS), right
intron retention junction (E_I_AS).
In the third step, we directly use the phase to translate
the sequence for the exons with the phase information in
Ensembl transcript. For the exons without the phase infor-
mation in Ensembl transcript, three translations are first
derived, each of which corresponds to a possible opening
reading frame (ORF) and generates one peptide. Then, the
automatic translation procedure calculates the length of
the peptide that map across the splicing site. Lastly, the
translation which contains the longest peptide is reserved
as alternative splicing peptide for SASD.
Online SASD server design
The online version of SASD database is a typical 3-tier
web application [10], with an SQL Server2012 database
at the backend database service layer as Data Access
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Tier, Apache/PHP server scripts to the middleware
application web server layer as Logic or Application
Tier, and CSS-driven web pages presented on the brow-
ser as Presentation Tier.
The result tables derived from the data generation
steps are imported into the SQL Server2012 database
(Figure 4). The pathway-gene, disease-gene, drug-gene,
organ-gene, protein-gene, gene-gene mapping tables
enable users to query the database with different IDs.
Pathway analysis
Pathway analysis is performed using the following data-
bases: Integrated Pathway Analysis Database (IPAD)
(http://bioinfo.hsc.unt.edu/ipad/) [36].
Conclusion
We developed SASD as a complement to the currently
existing alternative splicing databases to perform novel
alternative splicing identification on a biological con-
text such as pathway, disease, drug and organ specifi-
city or custom gene set with maximum coverage and
exclusive focus on alternative splicing. SASD integrates
the gene structure from Ensembl [19] and the context
(pathway, disease, drug and organ specificity) from
IPAD [20].
A single gene/transcript/protein, custom gene set,
pathway, disease, drug, organ related alternative splicing
can be searched, displayed, and downloaded from our
online user interface. The current SASD database can
help users discover novel alternative splicing from mass
spectrometry and interpret them at the context of path-
way, disease, drug and organ specificity or custom gene
set with maximum coverage and exclusive focus on
alternative splicing. We believe that it could help gener-
ate novel hypothesis on molecular risk factors and mole-
cular mechanisms of complex diseases, leading to
identification of potentially highly specific protein bio-
markers. Lastly, our database was demonstrated by com-
parison to other known databases and two case studies.
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Figure 4 Relational metadata model. The datasets were derived by the data generation pipeline.
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